Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 del |
Therapy | Decitabine |
Indication/Tumor Type | prostate adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 del | prostate adenocarcinoma | sensitive | Decitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Dacogen (decitabine) inhibited viability of castration-resistant prostate adenocarcinoma cells with loss of RB1 via knockout in culture and inhibited tumor growth in cell line xenograft models (PMID: 37967200). | 37967200 |
PubMed Id | Reference Title | Details |
---|---|---|
(37967200) | Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. | Full reference... |